PT-141 is the only FDA-approved peptide for sexual dysfunction in women and is widely used off-label in men. Complete guide to dosing, timing, and monitoring.
Quick Summary - PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women - Works centrally through melanocortin receptors in the brain -- not through vascular mechanisms like PDE5 inhibitors - Standard dose: 1.25-2 mg subcutaneous, 45 minutes to 1 hour before desired effect - Nausea is the most common side effect -- starts at lower doses and titrate up - No routine blood work required for healthy users; relevant labs depend on concurrent protocols
PT-141 works through a completely different mechanism than any other sexual function medication on the market. Viagra and Cialis (PDE5 inhibitors) work peripherally -- they increase blood flow to genital tissue. PT-141 works centrally -- it activates melanocortin receptors in the hypothalamus and limbic system, the brain regions that regulate sexual motivation and arousal.
This distinction has important practical implications. PT-141 works for both physical arousal and subjective desire -- the psychological experience of wanting sex, not just the physical response to stimulation. This is why it was developed specifically for hypoactive sexual desire disorder (HSDD) in women, a condition characterized primarily by reduced desire rather than reduced physical response.
For men, PT-141 is used off-label and produces effects complementary to (not competitive with) PDE5 inhibitors. Some men with partial response to Viagra find PT-141 provides the desire component that PDE5 inhibitors do not address.
PT-141 is an analog of alpha-MSH (alpha-melanocyte-stimulating hormone), a neuropeptide that activates melanocortin receptors (MC3R and MC4R) in the central nervous system. These receptors are expressed in the hypothalamus -- specifically in regions governing sexual behavior, appetite, and energy balance.
MC4R activation in the hypothalamus and limbic system drives the neurochemical cascade associated with sexual motivation: dopamine release, oxytocin activity, and the subjective experience of arousal and desire. This is the pathway that PT-141 engages.
Importantly, PT-141 also causes transient blood pressure elevation (typically 6-8 mmHg systolic increase peaking at 30-60 minutes post-dose). This is relevant for users with cardiovascular risk factors or hypertension.
FDA-approved female protocol (Vyleesi):
Dose: 1.75 mg subcutaneous, administered 45 minutes before anticipated sexual activity
Frequency: No more than once per 24 hours, no more than 8 times per month
Common off-label use (men and women):
Starting dose: 1.0-1.25 mg subcutaneous -- begin low to assess nausea response
Maintenance dose: 1.5-2.0 mg based on tolerance and desired effect
Timing: 45 minutes to 1 hour before desired effect
Frequency: As needed -- not a daily medication
Injection site: Abdomen or thigh -- standard subcutaneous technique
With or without food: Can be taken with food; food slightly reduces nausea but may modestly delay onset
Nausea is the most common reason users discontinue PT-141. It is dose-dependent and typically peaks 30-60 minutes after injection and resolves within 2-4 hours.
Strategies that reduce nausea:
PT-141 does not require specific blood work monitoring for healthy users. However, relevant labs depending on your situation:
Blood pressure check: If you have hypertension or cardiovascular risk factors, PT-141 transient blood pressure elevation (6-8 mmHg) should be discussed with your physician before use.
Hormone panel: If using PT-141 for sexual dysfunction, consider ruling out hormonal causes (low testosterone, low estradiol, thyroid dysfunction) that may be driving the underlying issue. PT-141 addresses desire but does not fix hormonal deficiency.
Melanocortin-related labs: PT-141 melanocortin activation can modestly affect ACTH and cortisol -- relevant only for users with adrenal conditions.
Does PT-141 work for erectile dysfunction?
PT-141 is not a first-line treatment for ED -- that is PDE5 inhibitors. However, PT-141 addresses the desire/arousal component that PDE5 inhibitors do not. Many men with ED find that combining PT-141 (desire) with a PDE5 inhibitor (blood flow) is more effective than either alone.
How long does PT-141 effect last?
Most users report effects lasting 6-12 hours from administration. The subjective arousal enhancement typically peaks at 2-4 hours post-injection.
Is PT-141 the same as Vyleesi?
Yes -- Vyleesi is the brand name for the FDA-approved 1.75 mg bremelanotide autoinjector. PT-141 refers to the same compound in compounded form, available at different doses.
Was PT-141 affected by the RFK reclassification?
PT-141/bremelanotide has an FDA-approved form (Vyleesi) and therefore was not part of the Category 2 restriction in the same way as the 14 reclassified peptides. It remains available through both the brand name and compounding channels.
Can women use PT-141 long-term?
The safety data from FDA approval trials supports use of up to 8 times per month. Long-term safety beyond 12 months has not been formally established. Discuss ongoing use with your prescriber.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →